allogeneic iPSC-derived natural killer cell immunotherapy / Shoreline Biosci - LARVOL DELTA

Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells (PRNewswire) - "Shoreline Biosciences...announced the presentation of data at the American Association for Cancer Research (AACR) annual meeting....Shoreline presented two posters demonstrating its novel methodologies to produce clinical scale iPSC-derived iNK cells. Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, 'off-the-shelf' production. Shoreline's methodology supports the production of phenotypically and functionally mature iNK cells from both wildtype and genetically engineered iPSCs."

Commercial • Oncology

SHORELINE BIOSCIENCES ANNOUNCES ORAL PRESENTATION on ipsc-derived NK cell (iNK) platform AT INNATE KILLER SUMMIT meeting 2022 (PRNewswire) - "Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage platforms (iMACs), today announced that management will deliver an oral presentation at the Innate Killer Summit 2022 meeting taking place in San Diego, CA from March 30-April 1, 2022."

Preclinical • Oncology